| Influenza |
1 |
0.95 |
| Vaccines |
0 |
0.86 |
| Pneumonia |
0 |
0.73 |
| Hepatitis B Virus |
0 |
0.65 |
| Tdap Vaccine |
0 |
0.64 |
| Biologic Therapy |
0 |
0.56 |
| Patient Safety |
0 |
0.56 |
| Pediatric Respiratory Infections |
0 |
0.51 |
| Primary Care |
0 |
0.48 |
| Influenza Vaccine |
0 |
0.45 |
| Pandemic |
0 |
0.4 |
| Respiratory Syncytial Virus (RSV) Infection |
0 |
0.35 |
| Antigens |
0 |
0.32 |
| Immunization |
0 |
0.32 |
| Pneumococcal Vaccine |
0 |
0.25 |
| Adverse Effects |
0 |
0.24 |
| Respiratory Tract Infections |
0 |
0.24 |
| Acute Rheumatic Fever |
0 |
0.18 |
| Rheumatic Fever |
0 |
0.17 |
| Antiviral Agents |
0 |
0.16 |
| Child |
0 |
0.16 |
| Fever |
0 |
0.16 |
| Group A Streptococcal Infection |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.16 |
| Hepatitis B Vaccine |
0 |
0.14 |
| Pertussis |
0 |
0.14 |
| COVID-19 |
0 |
0.12 |
| Health Insurance |
0 |
0.11 |
| Bacterial Pneumonia |
0 |
0.08 |
| Centers for Disease Control and Prevention |
0 |
0.08 |
| Cough |
0 |
0.08 |
| Diversity |
0 |
0.08 |
| Florida |
0 |
0.08 |
| Georgia |
0 |
0.08 |
| Hepatitis |
0 |
0.08 |
| Hepatitis A |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Maryland |
0 |
0.08 |
| Match |
0 |
0.08 |
| NHS |
0 |
0.08 |
| Point-of-Care |
0 |
0.08 |
| Otolaryngology |
0 |
0.07 |